Anúncio
Anúncio

TXG

TXG logo

10x Genomics, Inc. Class A Common Stock

20.47
USD
Patrocinado
+1.18
+6.14%
09 de jan., 15:59 UTC -5
Encerrado
exchange

Pós-Mercado

20.70

+0.23
+1.10%

Relatórios de Lucros TXG

Rácio de surpresa positiva

TXG separação 13 de 25 últimas estimativas.

52%

Próximo Relatório

Próxima semana
Data do Próximo Relatório
12 de jan. de 2026
Estimate for Q4 25 (Revenue/ EPS)
$157.54M
/
-$0.22
Mudanças implicadas de Q3 25 (Revenue/ EPS)
+5.73%
/
--
Mudanças implicadas de Q4 24 (Revenue/ EPS)
-4.54%
/
-45.00%

10x Genomics, Inc. Class A Common Stock earnings per share and revenue

On 06 de nov. de 2025, TXG reported earnings of -0.22 USD per share (EPS) for Q3 25, beating the estimate of -0.29 USD, resulting in a 24.40% surprise. Revenue reached 149.00 milhão, compared to an expected 143.91 milhão, with a 3.54% difference. The market reacted with a +17.31% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 18 analistas forecast an EPS of -0.22 USD, with revenue projected to reach 157.54 milhão USD, implying an aumentar of 0.00% EPS, and aumentar of 5.73% in Revenue from the last quarter.
FAQ
For Q3 2025, 10x Genomics, Inc. Class A Common Stock reported EPS of -$0.22, beating estimates by 24.4%, and revenue of $149.00M, 3.54% above expectations.
The stock price moved up 17.31%, changed from $13.00 before the earnings release to $15.25 the day after.
The next earning report is scheduled for 12 de jan. de 2026.
Based on 18 analistas, 10x Genomics, Inc. Class A Common Stock is expected to report EPS of -$0.22 and revenue of $157.54M for Q4 2025.
Verificar FXEmpire's Earnings Calendar for today's list of reporting companies.
Anúncio